Dr. Kaufman is a Professor in the UW Department of Ophthalmology and Visual Sciences at the University of Wisconsin School of Medicine and Public Health. His research centers on studies of the physiology, pharmacology, morphology, cell biology, genetic manipulation, neural control, biomechanics and aging of the aqueous humor formation and drainage and accommodative mechanisms in the non-human primate, seeking to understand the pathophysiology and develop new therapies for the human diseases of glaucoma and presbyopia.
Ocular Physiology (Anterior Segment)
Dr. Barney is an Associate Professor in the Department of Ophthalmology and Visual Sciences at the University of Wisconsin School of Medicine and Public Health. His clinical training is in all aspects of ocular immunology including uveitis and inflammatory disease of the anterior segment of the eye. His laboratory interests include the cellular signaling events on the ocular surface undergoing allergic reactions. He is a Principle Investigator on NIH funded research.
Dr. Miller is a Board Certified Veterinary Ophthalmologist and a Clinical Professor at the School of Veterinary Medicine, University of Wisconsin-Madison. His research and clinical interests focus on glaucoma in animals and, recently, he has worked extensively with non-human primate models of glaucoma.
Dr. Crosson serves as a member of the Executive Board and provides consulting on many aspects of vision science with a specific focus on pharmacology and animal models of elevated intraocular pressure, retinal degenerations and macular edema. Dr. Crosson is a Professor in the Department of Ophthalmology at the Medical University of South Carolina (MUSC). He is also Director of the Ola B. Williams Glaucoma Therapeutic Development Center and Senior Associate Dean for Research at MUSC. His research interests include ischemia, neovascularization, and neuroprotection.
OSOD is proud to welcome Dr. Craig Cross and Dr. Chuck O'Neill to the OSOD Executive Board. They each bring vast experience and new perspectives that go toward moving the company forward and increasing our capabilities.